EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice

Elia Tamagnini, Luca Simonelli, Martin Palus iD, Tanja Rezzonico Jost iD, Edoardo Lazzarini iD, Davide Mangani iD, Václav Hönig iD, Markéta Dvořáková iD, Dominik Arbon iD, Federica Gambini, Sara Lestani iD, Fabio Grassi iD und 4 weitere

Vaccines · 27.06.2026 · 14 (7) · 568

DOI: 10.3390/vaccines14070568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 27.06.2026. Verfasst von Elia Tamagnini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Biomedicine, Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, SPOPROVIR - Centre for Applied Research and Development of Diagnostic and Thera-peutic Procedures and Surveillance of Viral Infectious Disease, SPOPROVIR - Centre for Applied Research and Development of Diagnostic and Thera-peutic Procedures and Surveillance of Viral Infectious Disease and European Uni….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While vaccines are designed to elicit targeted immune responses, in some cases, the immunogenic molecules employed can inherently interact with broader host cellular pathways as a secondary consequence. This phenomenon can be exemplified by COVID-19 vaccines. COVID-19 vaccines, including mRNA platforms, use the SARS-CoV-2 spike protein as an immunogen to induce the production of neutralizing antibodies. The spike protein binds the ACE2 (angiotensin-converting enzyme 2) receptor on human cells, mediating viral entry and infection. ACE2 is widely expressed across multiple tissues and is a key component of the renin–angiotensin–aldosterone system (RAAS) that acts as a homeostatic regulator of systemic and local blood flow, blood pressure, cardiac function, fluid balance and immunity. Some studies have proposed the interaction between the spike protein and ACE2 as a possible contributing factor to rare adverse effects observed following COVID-19 vaccination, including myocarditis, pericarditis, thrombosis, and reported alterations in blood pressure, though these mechanisms remain to be fully elucidated.

Objectives

As a proof-of-concept approach in vaccine antigen development, we engineered SARS-CoV-2 spike mutants with impaired binding to the host receptor ACE2.

Methods

By rational design, we produced and validated in vitro and in vivo spike point mutants that do not effectively bind ACE2.

Results

The engineered spike mutants do not effectively bind the human entry receptor ACE2 while retaining the immunogenic properties equal to or better than the wild type spike and thus generate a protective response in animals when used as a vaccination agent.

Conclusions

By establishing a straightforward molecular strategy for rational vaccine design, this work demonstrates the feasibility of limiting specific antigen–host receptor interactions while maintaining immunogenicity. This approach may be applicable to future vaccination strategies where antigen interaction with host cells could potentially interfere with physiological pathways.

Schlagwörter

Stichwörter der Autor:innen

ACE2 receptorSARS-CoV-2off-target interferenceprotein engineeringspike proteinvaccine design

Autor:innen und Institutionen

  • Institute for Research in Biomedicine, Università della Svizzera italiana (USI), 6500 Bellinzona, Switzerland.
  • Laboratory of Arbovirology, Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 České Budějovice, Czech Republic.
  • Laboratory of Emerging Viral Infections, Veterinary Research Institute, CZ-62100 Brno, Czech Republic.
  • Department of Experimental Biology, Faculty of Science, Masaryk University, CZ-62500 Brno, Czech Republic.
  • Institute of Oncology Research, 6500 Bellinzona, Switzerland.
  • Institute for Translational Research (IRT), Faculty of Biomedical Sciences, Università Svizzera Italiana (USI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.

ORCID-Profile: Martin Palus, Tanja Rezzonico Jost, Edoardo Lazzarini, Davide Mangani, Václav Hönig, Markéta Dvořáková, Dominik Arbon, Sara Lestani, Fabio Grassi, Lucio Barile, Radislav Sedlacek

Förderung

  • Swiss National Science Foundation
  • SPOPROVIR - Centre for Applied Research and Development of Diagnostic and Thera-peutic Procedures and Surveillance of Viral Infectious Disease
  • SPOPROVIR - Centre for Applied Research and Development of Diagnostic and Thera-peutic Procedures and Surveillance of Viral Infectious Disease and European Uni…
  • Czech Academy of Sciences
  • SPOPROVIR—Centre for Applied Research and Development of Diagnostic and Therapeutic Procedures and Surveillance of Viral Infectious Diseases
  • European Union
  • Czech Science Foundation
  • Czech Centre for Phenogenomics

Zitieren

APA

Tamagnini, E., Simonelli, L., Palus, M., Jost, T. R., Lazzarini, E., Mangani, D., Hönig, V., Dvořáková, M., Arbon, D., Gambini, F., Lestani, S., Grassi, F., Barile, L., Pedotti, M., Sedlacek, R., & Varani, L. (2026). Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice. Vaccines, 14(7), 568. https://doi.org/10.3390/vaccines14070568

Vancouver

Tamagnini E, Simonelli L, Palus M, Jost TR, Lazzarini E, Mangani D, et al. Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice. Vaccines. 2026;14(7):568. doi:10.3390/vaccines14070568

BibTeX
@article{Tamagnini2026,
  author = {Tamagnini, Elia and Simonelli, Luca and Palus, Martin and Jost, Tanja Rezzonico and Lazzarini, Edoardo and Mangani, Davide and Hönig, Václav and Dvořáková, Markéta and Arbon, Dominik and Gambini, Federica and Lestani, Sara and Grassi, Fabio and Barile, Lucio and Pedotti, Mattia and Sedlacek, Radislav and Varani, Luca},
  title = {Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {568},
  doi = {10.3390/vaccines14070568}
}
Kostenlos starten →